Ustekinumab for the treatment of psoriasis | Zendy

Z.Z.N. Yiu | Zendy; Richard B. Warren | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ustekinumab for the treatment of psoriasis

Author(s) -

Z.Z.N. Yiu,

Richard B. Warren

Publication year - 2018

Publication title -

seminars in cutaneous medicine and surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.66

H-Index - 64

eISSN - 1558-0768

pISSN - 1085-5629

DOI - 10.12788/j.sder.2018.040

Subject(s) - ustekinumab , medicine , psoriasis , tolerability , observational study , dermatology , psoriasis area and severity index , randomized controlled trial , interleukin 23 , adverse effect , disease , interleukin 17 , adalimumab , cytokine

Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research